首页> 美国卫生研究院文献>Dialogues in Clinical Neuroscience >Rating scales in depression: limitations and pitfalls
【2h】

Rating scales in depression: limitations and pitfalls

机译:抑郁症的量表:局限性和陷阱

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Since the introduction of antidepressants to psychopharmacology in the 1960s, the Hamilton Depression Rating Scale (HAM-D) has been the most frequently used rating scale for depression. When used as a scale for prediction of outcome with antidepressants, the HAM-D, by its total score, has obtained limited use analogous to the Diagnostic and Statistical Manual of Mental Disorders. 4th ed (DSM-IV) diagnosis of major depression. Most research has been devoted to the use of the HAM-D to discriminate between placebo and active drugs or to show dose-response relationship in patients with major depression. An improvement in the total HAM-D score during a drug trial does not, however, in itself qualify the drug as an antidepressant, because the total score is not a sufficient statistic. The problem of statistical versus clinical significance when analyzing placebo-controlled trials, including dose-response relationship, is outlined, with the recommendation to use effect size statistics.
机译:自从1960年代将抗抑郁药引入心理药理学以来,汉密尔顿抑郁量表(HAM-D)一直是抑郁症最常用的量表。当用HAM-D作为抗抑郁药预后的量表时,其总分类似于《精神疾病诊断和统计手册》,获得了有限的使用。第四版(DSM-IV)诊断为严重抑郁症。大多数研究致力于使用HAM-D来区分安慰剂和活性药物,或显示重度抑郁症患者的剂量反应关系。但是,在药物试验期间,总HAM-D得分的提高本身并不能使该药物成为抗抑郁药,因为总得分还不够充分。概述了在分析安慰剂对照试验(包括剂量反应关系)时的统计意义与临床意义之间的问题,并建议使用效应量统计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号